Pharmaceutical firm Elan has announced that its revenues rose by 14% ($66m) to $526m in the second quarter of the year.
The company attributed the increase to a 30% rise in income from Tysabri, which is used to treat multiple sclerosis and Crohn's disease, and a 10% increase in revenues from Elan Drug Technologies.
Commentinng on the results, Elan executive vice-president and chief financial officer Shane Cooke said that there had been a 55% increase in the net number of patients using Tysabri since the first quarter. ..full story in RTE Business
